Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.178233 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Hnin Ei Ei Khine und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand. Hauptthemen laut MEDLINE: Heart Failure, Cisplatin, Mitochondria, Heart, Exenatide. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand, Mahidol University.
Abstract (Originalsprache)
Heart failure is a devastating consequence of chemotherapy, with mitochondrial dysfunction playing a key role in cardiac damage. Cisplatin (CP), a widely used chemotherapeutic agent, induces cardiotoxicity by increasing apoptosis and triggering inflammation. This study provides evidence that exendin-4 (Ex-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, exerts cardioprotective effects in H9c2 cardiomyoblasts against CP-induced injury. Ex-4 administration markedly restored mitochondrial bioenergetics, as evidenced by improved oxygen consumption and extracellular acidification rates, while preserving mitochondrial morphology and reversing fragmentation caused by CP. The observed effects were correlated with upregulation of markers involved in mitochondrial biogenesis (PGC1α, NRF1, ATP5A) and fusion process (OPA1, MFN1), accompanied by downregulation of mitochondrial fission markers (DNM1, FIS1). Ex-4 attenuated intracellular and mitochondrial reactive oxygen species (ROS) levels, repressed caspase-3/7 activity, and shifted apoptotic balance by enhancing Bcl-2 levels while diminishing BAX expression. Moreover, Ex-4 suppressed CP-triggered inflammatory responses by reducing TNFα and IL6 levels. Mechanistically, Ex-4 activated pro-survival signals (p-Akt and p-Erk1/2) and exerted cardioprotective effects through inhibition of p53 and NF-κB-dependent cascades. Pharmacological inhibition of p53 (pifithrin-α) or NF-κB (JSH-23) further amplified the protective effect of Ex-4 against CP-induced mitochondrial abnormalities, apoptosis, and inflammation, whereas activation of p53 (nutlin-3) or NF-κB (NF-κB activator 1) reversed these protective outcomes. Thus, Ex-4 emerges as a potent modulator of mitochondrial dysfunction and cellular stress through suppression of the p53 and NF-κB pathways, offering a promising therapeutic approach to mitigate CP-induced cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand; Center of Biopharmaceutical Science for Healthy Ageing, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand; C…
Förderung
- National Research Council of Thailand
- Mahidol University
Zitieren
APA
Khine, H. E. E., Mangmool, S., & Parichatikanond, W. (2025). Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178233
Vancouver
Khine HEE, Mangmool S, Parichatikanond W. Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178233
BibTeX
@article{Khine2025,
author = {Khine, Hnin Ei Ei and Mangmool, Supachoke and Parichatikanond, Warisara},
title = {Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.178233}
}
EUVIMED